Correction: A randomized controlled trial investigating the effects of PCSO-524®, a patented oil extract of the New Zealand Green Lipped Mussel (Perna canaliculus), on the behaviour, mood, cognition and neurophysiology of children and adolescents (aged 6–14 years) experiencing clinical and sub-clinical levels of hyperactivity and inattention: study protocol ACTRN12610000978066

  • James D Kean1,

    Affiliated with

    • David Camfield1,

      Affiliated with

      • Jerome Sarris1, 2,

        Affiliated with

        • Marni Kras1,

          Affiliated with

          • Richard Silberstein1,

            Affiliated with

            • Andrew Scholey1 and

              Affiliated with

              • Con Stough1Email author

                Affiliated with

                Nutrition Journal201312:113

                DOI: 10.1186/1475-2891-12-113

                Received: 7 August 2013

                Accepted: 7 August 2013

                Published: 8 August 2013

                The authors have identified an error in this published article [1].

                On page 4, under “Treatments” the milligrams listed have been calculated incorrectly. The sentence:

                “The Lyprinol capsules contain 18% EPA (46.8 mg) and 14% DHA (36.4 mg) per capsule.”

                Should read:

                “The Lyprinol capsules contain approximately 14% EPA (7.3 mg) and 11% DHA (5.5 mg) per capsule.”

                We apologize for this error.

                Authors’ Affiliations

                (1)
                Centre for Human Psychopharmacology, Swinburne University of Technology
                (2)
                Department of Psychiatry, University of Melbourne

                References

                1. Kean JD, Camfield D, Sarris J, Kras M, Silberstein R, Scholey A, Stough C: A randomized controlled trial investigating the effects of PCSO-524(R), a patented oil extract of the New Zealand green lipped mussel (perna canaliculus), on the behaviour, mood, cognition and neurophysiology of children and adolescents (aged 6--14 years) experiencing clinical and sub-clinical levels of hyperactivity and inattention: study protocol ACTRN1261000097806. Nutr J 2013, 12:100. Jul 16View Article

                Copyright

                © Kean et al.; licensee BioMed Central Ltd. 2013

                This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                Advertisement